ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth
factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or
Metastatic Non Small Cell Lung Cancer